Search
SOLACI Congress
HomePharmacologyOther

Other

View Category

Other

ESC 2020 | New SGLT2 Inhibitor Impacts Heart Failure Mortality

Empagliflozin is the second drug from the SGLT2 receptor inhibitor family to show a significant benefit in...
solaci -
Learn More
Other

ESC 2020 | New Drug Improves Functional Capacity in Hypertrophic Cardiomyopathy

In patients with hypertrophic cardiomyopathy, myosin inhibitor mavacamten plus optimal medical therapy improved hemodynamics, functional capacity, and...
solaci -
Learn More
Other

ESC 2020 | Atrial Fibrillation and Rhythm Control: A Matter of Time?

Early rhythm control therapy in patients recently diagnosed with atrial fibrillation reduces the risk of cardiovascular events...
solaci -
Learn More
Other

When and How Could Dexamethasone Be Useful in a COVID-19 Infection?

More details have emerged on the group of COVID-19 patients who received dexamethasone in the RECOVERY trial. These...
solaci -
Learn More
Other

Peripheral Artery Disease: Underestimated and Undertreated

Compared against coronary artery disease (CAD) or cerebrovascular disease patients, peripheral artery disease (PAD) patients have lower...
solaci -
Learn More
Chronic Ischemic cardiopathy

Olive Oil and Cardiovascular Risk: The Higher the Consumption, the Lower the Risk?

High olive oil intake was associated with lower risk of coronary heart disease and cardiovascular disease in...
solaci -
Learn More
Other

SPARCL: Highly Effective Prevention of New Events with Atorvastatin after a Stroke

In patients with recent stroke or transient ischemic attack, the total number of vascular events prevented by...
solaci -
Learn More
Other

A New Molecule to Prevent Contrast-Induced Kidney Injury

Administrating Recombinant Human C1-Esterase-Inhibitor (rhC1INH) before coronary angiography might mitigate contrast induced kidney injury. In addition, it...
solaci -
Learn More

SOLACI is the reference organization for Latin American cardiovascular interventionism.

Last News

TRILUMINATE: Liver and Kidney Failure in Tricuspid Valve Edge-to-Edge Repair

Dr. Carlos Fava - 0
Severe tricuspid regurgitation (TR) will affect roughly 3% of the 65+ population and may lead to liver and kidney failure, which will cause ascites...

Secondary Access in TAVI: Is Transradial Approach our Best Bet?

Dr. Omar Tupayachi - 0
In some countries, transcatheter aortic valve implantation (TAVI) has become the treatment of choice for patients with severe symptomatic aortic stenosis. Primary transfemoral access...

FAVOR III Europa Sub-Analysis: Coronary Revascularization Deferral Based On QFR vs FFR

Dr. Andrés Rodríguez - 0
When it comes to intermediate coronary lesion revascularization decision making, functional assessment is the recommended. At present, several indices are used, such as fractional...

Institutional News

Cuba Sessions 2025 | Young Interventional Cardiologists Contest

solaci - 0
Call for Case Submission L SOLACI Regional Sessions - 18° Central America & The Caribbean Region - It is with great pleasure that we hereby...

Hemodynamics and Interventional Cardioangiology Hybrid Training Course SOLACI-CACI

solaci - 0
We are now open for registration to the hybrid training course on Hemodynamics and Interventional Cardioangiology for Technicians and Nurses SOLACI-CACI 2025 Find all course...

Check out the best images of the El Salvador 2024 Sessions

solaci - 0
Review the highlights of the XLIX SOLACI Regional Sessions held at the Intercontinental Hotel in San Salvador, El Salvador between November 7 and 8,...

Access

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Terms of Use -Privacy Policy